ClinConnect ClinConnect Logo
Search / Trial NCT02673502

Pre-operative Carbohydrate Drink to Preserve Peri-operative Insulin Sensitivity

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Feb 3, 2016

Trial Information

Current as of June 20, 2025

Completed

Keywords

Carbohydrate Drink Post Operative Complication Insulin Resistance Fasting Blood Glucose

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. At least 18 years of age
  • 2. Planned laparoscopic partial colon resection for non-metastatic neoplastic or benign disease (including right, transverse, left or sigmoid))
  • 3. HbA1c less than or equal to 5.7%
  • 4. Not receiving any kind of glucose lowering medication.
  • Exclusion Criteria:
  • 1. Are already diagnosed with diabetes or pre diabetes (HbA1c \> 5.7%)
  • 2. Are pre-diabetic receiving glucose lowering intervention (any glucose lowering medication)
  • 3. Have renal or liver dysfunction (serum creatinine above 1.4 mg/dL in women and 1.5 mg/dL in men, bilirubin \>2.9 mg/dL)
  • 4. Will undergo extended resection of adjacent organs
  • 5. Non-elective operations
  • 6. New stoma created
  • 7. Have conditions precluding participation in the ERAS pathway (e.g. dementia, disabling orthopedic and neuromuscular disease, psychosis)
  • 8. Have conditions requiring preoperative fasting: documented gastroparesis, patient on metoclopramide and/or domperidone, achalasia, dysphagia (any difficulty with swallowing), or Fluid restriction (e.g. dialysis, pulmonary oedema, congestive heart failure).
  • 9. Have cardiac abnormalities, severe end-organ disease such as cardiac failure (New York Heart Association classes III-IV), chronic obstructive pulmonary disease (documented by abnormal pulmonary function test), morbid obesity (BMI \>40 kg/m2), anemia (hematocrit \< 30 %, hemoglobin \<100g/L, albumin \< 25mg/dl)
  • 10. Have received steroids for longer than 30 days
  • 11. Have poor English or French comprehension.

About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre

The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.

Locations

Montreal, Quebec, Canada

Patients applied

0 patients applied

Trial Officials

Liane Feldman, MD

Principal Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

Francesco Carli, MD

Principal Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials